FindTrial
Sign In

CX-072

DRUG3 trials

Sponsors

CytomX Therapeutics

Conditions

Breast CancerBreast NeoplasmsBreast Neoplasms, Hormone Receptor Positive/HER2 NegativeBreast Neoplasms, Triple-NegativeLymphomaNeoplasmsSolid TumorUnresectable or Metastatic Melanoma

Phase 1

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
TerminatedNCT03013491
CytomX TherapeuticsLymphoma, Solid Tumor
Start: 2017-01-19End: 2020-10-27Updated: 2025-06-17

Phase 2

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
TerminatedNCT03993379
CytomX TherapeuticsSolid Tumor, Unresectable or Metastatic Melanoma
Start: 2019-11-20End: 2020-05-21Updated: 2025-12-26
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
CompletedNCT04596150
CytomX TherapeuticsBreast Cancer, Breast Neoplasms, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative +2
Start: 2020-12-29End: 2023-06-02Updated: 2024-01-23

Related Papers

Abstract P4-01-15: Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)
Cancer Research2023-03-015 citations
Abstract OT1-12-02: Trial in progress: Phase 2, open-label study to evaluate the safety and efficacy of praluzatamab ravtansine in metastatic HER2 non-amplified breast cancer as monotherapy and combination with pacmilimab
Cancer Research2022-02-15
CX-072 (pacmilimab), a Probody<b> <sup>®</sup> </b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
Journal for ImmunoTherapy of Cancer2021-07-0135 citations
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
Journal for ImmunoTherapy of Cancer2021-07-0123 citations
Evidence of intratumoral localization, activation, and immunomodulatory effect of CX-072, a probody therapeutic targeting PD-L1, in a phase I/II trial.
Journal of Clinical Oncology2020-05-2010 citations
Preliminary population pharmacokinetics supports phase II dose selection for masked anti-PD-L1 antibody CX-072.
Journal of Clinical Oncology2020-05-202 citations
PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab.
Journal of Clinical Oncology2020-05-201 citations
Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
Clinical Cancer Research2020-01-1749 citations
CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.
Journal of Clinical Oncology2019-05-2011 citations
Abstract P6-18-31: PROCLAIM-CX-072: Monotherapy for advanced triple negative breast cancer with skin metastases in a phase 1-2 trial of the PD-L1 probody therapeutic CX-072
Cancer Research2019-02-151 citations
Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors
Annals of Oncology2018-10-012 citations
Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors
Annals of Oncology2018-10-012 citations
Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology2018-05-203 citations
Preliminary interim results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic (Pb-Tx) CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology2018-05-202 citations
Preliminary single-dose clinical pharmacokinetics of an anti–PD-L1 Probody therapeutic (Pb-Tx) in cancer patients.
Journal of Clinical Oncology2018-05-20
PROCLAIM-001: A first-in-human trial to assess tolerability of the protease-activatable anti-PD-L1 Probody CX-072 in solid tumors and lymphomas.
Journal of Clinical Oncology2017-05-202 citations